These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12057618)

  • 1. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant.
    Desombere I; Van der Wielen M; Van Damme P; Stoffel M; De Clercq N; Goilav C; Leroux-Roels G
    Vaccine; 2002 Jun; 20(19-20):2597-602. PubMed ID: 12057618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
    Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
    Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.
    Levie K; Gjorup I; Skinhøj P; Stoffel M
    Scand J Infect Dis; 2002; 34(8):610-4. PubMed ID: 12238579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TH1 and TH2 responses are influenced by HLA antigens in healthy neonates vaccinated with recombinant hepatitis B vaccine.
    Jafarzadeh A; Shokri F
    Iran J Allergy Asthma Immunol; 2012 Dec; 11(4):308-15. PubMed ID: 23264407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
    Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
    Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prophylactic hepatitis B vaccine with a novel adjuvant system.
    Thoelen S; De Clercq N; Tornieporth N
    Vaccine; 2001 Mar; 19(17-19):2400-3. PubMed ID: 11257368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
    Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
    Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
    Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.
    Thoelen S; Van Damme P; Mathei C; Leroux-Roels G; Desombere I; Safary A; Vandepapeliere P; Slaoui M; Meheus A
    Vaccine; 1998 Apr; 16(7):708-14. PubMed ID: 9562690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
    Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
    Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
    Heron L; Selnikova O; Moiseieva A; Van Damme P; van der Wielen M; Levie K; Hoet B; Stoffel M
    Vaccine; 2007 Apr; 25(15):2817-22. PubMed ID: 17276552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine.
    Young MD; Rosenthal MH; Dickson B; Du W; Maddrey WC
    Vaccine; 2001 May; 19(25-26):3437-43. PubMed ID: 11348708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
    Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
    Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation.
    Fabrizi F; Andrulli S; Bacchini G; Corti M; Locatelli F
    Nephrol Dial Transplant; 1997 Jun; 12(6):1204-11. PubMed ID: 9198052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.